We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Blackstone Inc | NYSE:BX | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
1.05 | 0.89% | 118.54 | 118.70 | 116.39 | 118.63 | 1,231,583 | 18:33:59 |
By Colin Kellaher
Praxis Precision Medicines Inc. on Friday said it expects to sell 7.4 million shares at between $16 and $18 apiece in its initial public offering.
At the $17 midpoint of that range, the Cambridge, Mass., clinical-stage biopharmaceutical company said it expects net proceeds of about $113.7 million, or roughly $131.2 million if the underwriters exercise an option to buy an additional 1.11 million shares.
Praxis, which is developing therapies for central-nervous-system disorders, said the proceeds, coupled with its existing resources, will be sufficient to fund its operations for at least the next 18 months.
In a filing with the U.S. Securities and Exchange Commission, Praxis said it would have about 35.3 million shares outstanding after the IPO, assuming exercise of the overallotment option, for a valuation of about $600 million at the $17-a-share midpoint.
Entities affiliated with investment firm Blackstone Group Inc. currently own about 31.8% of Praxis, which has applied to list its shares on the Nasdaq Global Market under the symbol PRAX.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 09, 2020 06:56 ET (10:56 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Blackstone Chart |
1 Month Blackstone Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions